6/26/2025

Incyte stock popped Thursday after the company's board appointed Bill Meury as its new CEO, replacing Herve Hoppenot, who is retiring.

Source: Yahoo

6/26/2025

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug developer now at a crossroads.

Source: Yahoo

6/26/2025

Subjects received subcutaneous doses of either 150mg or 300mg every four weeks over a 24-week period.

Source: Yahoo

6/26/2025

ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target ProFound to leverage its ProFoundry™ Platform to mine the expanded proteome to identify previously unknown proteins as novel drug targets for cardiovascular disease CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProFound™ Therapeutics, a company pioneering the expanded human proteome to develop first-in-class medicines for multiple diseases, today announ

Source: Yahoo

6/26/2025

The global retinitis pigmentosa market, valued at $11.31 billion in 2024, is expected to grow to $25.87 billion by 2034, driven by gene therapy advancements, aging populations, and strategic industry collaborations. North America leads, while Asia-Pacific demonstrates rapid growth. Key players include Johnson & Johnson and Novartis AG. Retinitis Pigmentosa Market Retinitis Pigmentosa Market Dublin, June 26, 2025 (GLOBE NEWSWIRE) -- The "Retinitis Pigmentosa Market Opportunities and Strategies to

Source: Yahoo

6/26/2025

The transaction was approved by both companies' boards and includes a significant premium over recent stock prices for Regulus shareholders.

Source: Yahoo

6/26/2025

In the first quarter, the Victory Diversified Stock Fund A-Shares (without sales charge) underperformed its S&P 500®Index benchmark by 95 basis points.

Source: SeekingAlpha

6/26/2025

Source: SeekingAlpha

6/25/2025

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis. “We are pleased to complete this transaction and take the next step in advancing clinical development for a potential fir

Source: Yahoo

6/25/2025

The Victory RS International Fund returned +6.75% (Class A Shares at net asset value) for the period, while its benchmark, the MSCI EAFE Index, returned +6.86%.

Source: SeekingAlpha

6/25/2025

Novartis AG offers growth potential with a balanced drug portfolio, manageable debt, and shares priced below fair value. Click for my updated look at NVS stock.

Source: SeekingAlpha

6/25/2025

Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc. (“Regulus”), in exchange for (i) $7.00 in cash per share, subject to any applicable withholding and without interest thereon, plus (ii) one conting

Source: Yahoo

6/24/2025

We came across a bullish thesis on Novartis AG (NVS) on Stock Analysis Compilation’s Substack. In this article, we will summarize the bulls’ thesis on NVS. Novartis AG (NVS)’s share was trading at $120.77 as of 12th June. NVS’s trailing and forward P/E were 18.93 and 14.31 respectively according to Yahoo Finance. Novartis presents a compelling long-term […]

Source: Yahoo

6/24/2025

JPM's strong NII outlook, NVS's blockbuster pipeline, and T's wireless momentum anchor today's top analyst picks.

Source: Yahoo

6/24/2025

Source: SeekingAlpha

6/24/2025

The global brain cancer treatment market is rapidly evolving, driven by the increasing incidence of brain cancer and advancements in medical technology focusing on personalized medicine. With immunotherapies and genetically tailored treatments gaining traction, the market is shifting from traditional methods to more targeted solutions. The discovery of genetic markers facilitates precision medicine strategies, marking significant milestones with new biologics and therapies. North America leads,

Source: Yahoo

6/24/2025

The gene and cell therapies market targeting central nervous system (CNS) disorders is rapidly advancing, driven by increasing incidences of conditions like Parkinson's, Alzheimer's, and multiple sclerosis. With current treatments often ineffective, there's a pressing demand for innovative solutions. Technological advancements such as CRISPR and stem cell therapy are propelling market growth by offering precise, effective treatments. However, high development and manufacturing costs pose challen

Source: Yahoo

6/23/2025

Discover why Genmab A/S stands out as a high-margin biotech with strong partnerships, robust growth prospects, and undervalued metrics. Click for more on GMAB.

Source: SeekingAlpha

6/23/2025

Basel, June 23, 2025 – Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc. (“Regulus”), in exchange for (i) $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus

Source: Yahoo

6/20/2025

Five years ago, scientists and investors were excited about gene therapy offering one-and-done cures for deadly diseases. Today, much of the enthusiasm has dried up.

Source: Yahoo